Developer docs
API playgroundTry for free, no card

Search company profiles

Ourobionics

Full company profile

uuid000hdst

Namestring
Ourobionics
Legal namestring
Ourobionics
Websiteurl
ourobionics.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ourobionics is a Dutch deep-technology company founded in March 2021 and headquartered in Wageningen, The Netherlands. It develops 4D biofabrication technology that integrates human tissue engineering with embedded biosensors to produce "cyborganic" tissue constructs intended for preclinical drug and compound testing. The company targets four enterprise verticals — pharmaceutical, cosmetic, chemical, and Medtech — alongside academic and research institutions, with an explicit mission to replace animal testing, accelerate drug discovery, and lower pharmaceutical R&D costs.

The company's technological core is a patent-pending 3D bio-electric field biofabrication methodology licensed from University College London (UCL) and originated in Professor Suwan N. Jayasinghe's BioPhysics Group, whose underlying science is documented in over 150 scientific publications. This methodology is operationalized through CHIMERA, a 5-in-1 biofabrication device that integrates bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and conventional extrusion into a single platform with nanoscale resolution while preserving cell viability. The portfolio further includes UNIQUE-SKIN, a full-thickness in-vitro human skin model with epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network, and a line of human-derived biomaterials — HumaDerm collagen, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix ECM — for tissue engineering applications.

Ourobionics operates three distinct revenue streams: capital sales of the CHIMERA device to academic and research institutes (pricing undisclosed), custom development of tailored tissue models for enterprise customers under direct engagement, and unit-priced sales of human-derived biomaterials through a company-owned e-commerce storefront at roughly €97–€635 per SKU. The company monetizes through one-time equipment and license sales rather than recurring subscriptions, with go-to-market executed via enterprise field sales, conference presence (TERMIS, ScSB), and direct digital channels. To date, capital has been raised exclusively through non-dilutive Dutch and EU grant programs — notably the NXTGEN HIGHTECH National Growth Fund initiative (a EUR 1 billion multi-project program running through 2030) and the EU REACT-EU-backed ION+2 fund managed by Oost NL — supplemented by strategic R&D co-development with partners including the Smart Biomaterials Consortium (SBMC), Burn Research Lab, Hair Science Clinic, CyboSense, and Health~Holland.

Short descriptiontext

Ourobionics is a Dutch deep-technology company that develops 4D biofabrication platforms — including the CHIMERA 5-in-1 device — and sensor-embedded human tissue models (notably UNIQUE-SKIN) for pharmaceutical, cosmetic, chemical, and Medtech customers seeking alternatives to animal testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D biofabrication devices, human tissue models, regenerative medicine technology, human-derived biomaterials, bioprinting research tools
Industry4 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Biofabrication Technology
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CHIMERA Biofabrication Device Sales
TypeOne Time License
Description

Sale of CHIMERA 5-in-1 biofabrication device to academic institutions and research institutes. CHIMERA v1.0 has been released and is available for academic institutes with special conditions for first ambassadors.

ourobionics.com
2Human Tissue Models
TypeOne Time License
Description

Development and production of tailored human tissue models with embedded sensors for pharmaceutical, cosmetic, chemical, and Medtech companies for drug/compound testing.

ourobionics.com
3Human-Derived Biomaterials
TypeOne Time License
Description

Sale of human-derived biomaterials including HumaDerm (collagen), Huma OsteoGelatin, and HumaMatrix products for tissue engineering and regenerative medicine research.

ourobionics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details8 tiers
1HumaDerm Human Skin Collagen Type I, Lyophilized
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €523.17 excluding VAT

ourobionics.com
2HumaDerm Human Skin Collagen Type I, Solution
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €201.80 excluding VAT

ourobionics.com
3HumaDerm Human Skin Collagen Type I, Lyophilized, Insoluble
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €276.53 excluding VAT

ourobionics.com
4Huma OsteoGelatin Type A, Lyophilized, Medium Bloom
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €97.16 excluding VAT

ourobionics.com
5Huma OsteoGelatin Type A, Lyophilized, High Bloom
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €97.16 excluding VAT

ourobionics.com
6Huma OsteoGelMA Type A, Lyophilized, Medium Bloom
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€635.28 excluding VAT

ourobionics.com
7HumaMatrix, Native Human-Derived ECM, Solution
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €156.95 excluding VAT

ourobionics.com
8HumaMatrix, Native Human-Derived ECM, Lyophilized
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From €164.43 excluding VAT

ourobionics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1CHIMERA
Description

5-in-1 biofabrication device utilizing bioelectric field technology for depositing cells and biomaterials in complex 3D matrices enabling tissue formation. Features capabilities including bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and extrusion.

ourobionics.com
+5 more records
Core offering1 text field

Ourobionics develops and produces human tissue models with embedded biosensors and the CHIMERA 5-in-1 biofabrication device, leveraging proprietary 3D bio-electric field technology to deposit cells and biomaterials into complex 3D matrices. The company also sells a line of human-derived biomaterials (HumaDerm, Huma OsteoGelatin, HumaMatrix) for tissue engineering and regenerative medicine applications, serving pharmaceutical, cosmetic, chemical, and Medtech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90% of drugs tested on animals ultimately fail in human trials - Ourobionics aims to solve that bottleneck
+2 more records
Product overview1 text field

Ourobionics is a deep technology company in 4D Bioprinting that combines a core CHIMERA biofabrication platform with advanced tissue models and human-derived biomaterials. The CHIMERA platform serves as the foundational technology enabling five biofabrication approaches (Bio-electrospraying, Cell-electrospinning, Bio-electrojetting, Melt-electrowriting, and Extrusion) to create complex human tissues. The UNIQUE-SKIN product represents the company's advanced tissue modeling offering—a full-thickness human skin model with hair follicles, sweat glands, and vascular networks. Complementing these are Human-Derived Biomaterials including HumaDerm collagen products, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix for tissue engineering and regenerative medicine applications. The company operates primarily in the pharmaceutical, cosmetic, chemical, and Medtech sectors.

Product and service7 records
1CHIMERA 5-in-1 Biofabrication Device
CategoryBiofabrication Equipment
Description

In-house developed 5-in-1 biofabrication device that uses a patent-pending 3D bio-electric field to deposit cells and biomaterials in complex 3D matrices with nanoscale resolution, enabling high-throughput complex tissue formation. Designed for academic and research institutes, with ambassador pricing for first customers.

2UNIQUE-SKIN Full-Thickness Human Skin Model
CategoryTissue Models
Description

Next-generation full-thickness in-vitro human skin model featuring epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network. Designed for preclinical drug testing, tissue therapeutics, and regenerative medicine research with planned biosensor integration.

3Custom Tailored Human Tissue Models
CategoryTissue Models
Description

Bespoke human tissue models with embedded biosensors developed for pharmaceutical, cosmetic, chemical, and Medtech companies for drug discovery, safety testing, efficacy testing, and new treatment development.

4HumaDerm Human Skin Collagen Type I
CategoryBiomaterials
Description

Native human skin type I collagen available in Lyophilized, Solution, and Insoluble forms, offering excellent biocompatibility and structural integrity for tissue culture coating and tailor-made hydrogels in tissue engineering.

5Huma OsteoGelatin Type A
CategoryBiomaterials
Description

First and only human bone gelatin available in Medium Bloom and High Bloom variants, offering high biodegradability and low toxicity for surface coating and hydrogel encapsulations in regenerative medicine applications.

6Huma OsteoGelMA Type A
CategoryBiomaterials
Description

Metacrylated human gelatin for tuneable 3D hydrogels that cure under UV light with a photoinitiator such as Irgacure 2959, providing improved mechanical properties and stability of tissue constructs.

7HumaMatrix Native Human-Derived ECM
CategoryBiomaterials
Description

Human-derived extracellular matrix that mimics the natural cellular environment, available in Solution and Lyophilized forms and ready-to-use as a coating agent or hydrogel component in tissue engineering and regenerative medicine.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Smart Biomaterials Consortium (SBMC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-14
Description

Strategic R&D partnership to accelerate development of UNIQUE SKIN - a next-generation in-vitro human skin model using the patented CHIMERA 3D bioprinter. SBMC provides laboratory infrastructure, analytical support, and facilities for testing and scaling up technology.

ourobionics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-24
Description

EMARS project collaboration to develop hair-bearing skin constructs for improving treatment of deep wounds and hair loss. Burn Research Lab provides clinical expertise and research facilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-24
Description

EMARS project collaboration optimizing hair graft storage conditions, determining conditions for hair regeneration from stem cells, and incorporating stem cells into skin constructs.

Strategic tierCoreTypeTechnology or Integration
Description

Partner providing advanced biomarker bioelectronic biosensor technology integrated into the UNIQUE SKIN project for real-time monitoring capabilities.

Strategic tierFlagshipTypeTechnology or Integration
Description

Technology invented by Professor Suwan N. Jayasinghe at UCL, licensed to Ourobionics. The bio-electric field technology has been proven in over 150 publications from UCL's BioPhysics Group.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch organ-on-chip company selling OrganoPlate products to pharma for drug screening. Directly competes with Ourobionics' UNIQUE-SKIN in preclinical human-tissue testing, with overlapping customer base and GTM motion.

TypeDirect peer
Description

Spanish bioprinting hardware manufacturer offering modular 3D bioprinters and bioinks. Overlaps with Ourobionics on the CHIMERA device side of the business, serving academic and clinical regenerative medicine customers.

TypeDirect peer
Description

Pioneer in 3D bioprinted human tissue for preclinical drug testing. Competes head-to-head with Ourobionics in the pharma tissue-model use case and shares the same regulatory tailwind from animal-testing phase-out.

TypeDirect peer
Description

Swedish leader in bioprinting hardware and biomaterials. Sells bioprinters and bioinks to academic and pharma customers globally — directly overlapping with Ourobionics' CHIMERA device and HumaDerm biomaterial offerings. Most comparable peer on business model and customer base.

TypeDirect peer
Description

German company developing multi-organ-chip (MOC) platforms for substance testing. Comparable product–market fit in pharma/cosmetics preclinical testing and similar European footprint to Ourobionics.

TypeBroad incumbent
Description

Large industrial 3D printing incumbent that has explored bioprinting and regenerative medicine applications. Adjacent rather than direct — overlapping on hardware but not focused on Ourobionics' tissue-model niche.

TypeDirect peer
Description

US organ-on-chip platform using Organs-on-Chips technology for pharma drug development. Competes for the same pharma preclinical-testing budget as Ourobionics' tissue models, particularly in safety and efficacy testing.

8Aspect Biosystems
TypeDirect peer
Description

Canadian biotech using microfluidic 3D bioprinting to create functional human tissues for therapeutic and drug-discovery applications. Comparable modality (biofabrication platform + tissue products) and target customers.

TypeBroad incumbent
Description

Global 3D printing leader with historical investments in bioprinting and medical applications. Comparable on the printing-hardware axis but broader portfolio and not specialized in tissue engineering like Ourobionics.

TypeDirect peer
Description

French company commercializing laser-assisted bioprinting for tissue engineering and in-vitro models. Overlaps with Ourobionics on bioprinting-hardware-plus-tissue-models positioning, particularly for cosmetic and pharma applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ourobionics

Biofabrication Technologyourobionics.com

Ourobionics is a Dutch deep-technology company that develops 4D biofabrication platforms — including the CHIMERA 5-in-1 device — and sensor-embedded human tissue models (notably UNIQUE-SKIN) for pharmaceutical, cosmetic, chemical, and Medtech customers seeking alternatives to animal testing.

What Ourobionics does

Ourobionics is a Dutch deep-technology company founded in March 2021 and headquartered in Wageningen, The Netherlands. It develops 4D biofabrication technology that integrates human tissue engineering with embedded biosensors to produce "cyborganic" tissue constructs intended for preclinical drug and compound testing. The company targets four enterprise verticals — pharmaceutical, cosmetic, chemical, and Medtech — alongside academic and research institutions, with an explicit mission to replace animal testing, accelerate drug discovery, and lower pharmaceutical R&D costs.

The company's technological core is a patent-pending 3D bio-electric field biofabrication methodology licensed from University College London (UCL) and originated in Professor Suwan N. Jayasinghe's BioPhysics Group, whose underlying science is documented in over 150 scientific publications. This methodology is operationalized through CHIMERA, a 5-in-1 biofabrication device that integrates bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and conventional extrusion into a single platform with nanoscale resolution while preserving cell viability. The portfolio further includes UNIQUE-SKIN, a full-thickness in-vitro human skin model with epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network, and a line of human-derived biomaterials — HumaDerm collagen, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix ECM — for tissue engineering applications.

Ourobionics operates three distinct revenue streams: capital sales of the CHIMERA device to academic and research institutes (pricing undisclosed), custom development of tailored tissue models for enterprise customers under direct engagement, and unit-priced sales of human-derived biomaterials through a company-owned e-commerce storefront at roughly €97–€635 per SKU. The company monetizes through one-time equipment and license sales rather than recurring subscriptions, with go-to-market executed via enterprise field sales, conference presence (TERMIS, ScSB), and direct digital channels. To date, capital has been raised exclusively through non-dilutive Dutch and EU grant programs — notably the NXTGEN HIGHTECH National Growth Fund initiative (a EUR 1 billion multi-project program running through 2030) and the EU REACT-EU-backed ION+2 fund managed by Oost NL — supplemented by strategic R&D co-development with partners including the Smart Biomaterials Consortium (SBMC), Burn Research Lab, Hair Science Clinic, CyboSense, and Health~Holland.

Ourobionics firmographics

Firmographics
Name
Ourobionics
Legal name
Ourobionics
Website
https://ourobionics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Ourobionics is a Dutch deep-technology company that develops 4D biofabrication platforms — including the CHIMERA 5-in-1 device — and sensor-embedded human tissue models (notably UNIQUE-SKIN) for pharmaceutical, cosmetic, chemical, and Medtech customers seeking alternatives to animal testing.
Ownership category
akta.pro rank

Ourobionics industry classification

Industry
Product category
Biofabrication Technology
NAICS
Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • 3D biofabrication devices
  • Human tissue models
  • Regenerative medicine technology
  • Human-derived biomaterials
  • Bioprinting research tools

Where Ourobionics is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Ourobionics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. CHIMERA Biofabrication Device Sales: Sale of CHIMERA 5-in-1 biofabrication device to academic institutions and research institutes. CHIMERA v1.0 has been released and is available for academic institutes with special conditions for first ambassadors.
  2. Human Tissue Models: Development and production of tailored human tissue models with embedded sensors for pharmaceutical, cosmetic, chemical, and Medtech companies for drug/compound testing.
  3. Human-Derived Biomaterials: Sale of human-derived biomaterials including HumaDerm (collagen), Huma OsteoGelatin, and HumaMatrix products for tissue engineering and regenerative medicine research.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHumaDerm Human Skin Collagen Type I, Lyophilized
Unit PricingPay-as-you-goHumaDerm Human Skin Collagen Type I, Solution
Unit PricingPay-as-you-goHumaDerm Human Skin Collagen Type I, Lyophilized, Insoluble
Unit PricingPay-as-you-goHuma OsteoGelatin Type A, Lyophilized, Medium Bloom
Unit PricingPay-as-you-goHuma OsteoGelatin Type A, Lyophilized, High Bloom
Unit PricingPay-as-you-goHuma OsteoGelMA Type A, Lyophilized, Medium Bloom
Unit PricingPay-as-you-goHumaMatrix, Native Human-Derived ECM, Solution
Unit PricingPay-as-you-goHumaMatrix, Native Human-Derived ECM, Lyophilized

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Ourobionics product offering

Product offering

Core offering

Ourobionics develops and produces human tissue models with embedded biosensors and the CHIMERA 5-in-1 biofabrication device, leveraging proprietary 3D bio-electric field technology to deposit cells and biomaterials into complex 3D matrices. The company also sells a line of human-derived biomaterials (HumaDerm, Huma OsteoGelatin, HumaMatrix) for tissue engineering and regenerative medicine applications, serving pharmaceutical, cosmetic, chemical, and Medtech customers.

Product overview

Ourobionics is a deep technology company in 4D Bioprinting that combines a core CHIMERA biofabrication platform with advanced tissue models and human-derived biomaterials. The CHIMERA platform serves as the foundational technology enabling five biofabrication approaches (Bio-electrospraying, Cell-electrospinning, Bio-electrojetting, Melt-electrowriting, and Extrusion) to create complex human tissues. The UNIQUE-SKIN product represents the company's advanced tissue modeling offering—a full-thickness human skin model with hair follicles, sweat glands, and vascular networks. Complementing these are Human-Derived Biomaterials including HumaDerm collagen products, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix for tissue engineering and regenerative medicine applications. The company operates primarily in the pharmaceutical, cosmetic, chemical, and Medtech sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • CHIMERA: 5-in-1 biofabrication device utilizing bioelectric field technology for depositing cells and biomaterials in complex 3D matrices enabling tissue formation. Features capabilities including bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and extrusion.
  • UNIQUE-SKIN
  • HumaDerm
  • HumaMatrix
  • Huma OsteoGelatin
  • Huma OsteoGelMA

Products and services

  • CHIMERA 5-in-1 Biofabrication Device In-house developed 5-in-1 biofabrication device that uses a patent-pending 3D bio-electric field to deposit cells and biomaterials in complex 3D matrices with nanoscale resolution, enabling high-throughput complex tissue formation. Designed for academic and research institutes, with ambassador pricing for first customers.
  • UNIQUE-SKIN Full-Thickness Human Skin Model Next-generation full-thickness in-vitro human skin model featuring epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network. Designed for preclinical drug testing, tissue therapeutics, and regenerative medicine research with planned biosensor integration.
  • Custom Tailored Human Tissue Models Bespoke human tissue models with embedded biosensors developed for pharmaceutical, cosmetic, chemical, and Medtech companies for drug discovery, safety testing, efficacy testing, and new treatment development.
  • HumaDerm Human Skin Collagen Type I Native human skin type I collagen available in Lyophilized, Solution, and Insoluble forms, offering excellent biocompatibility and structural integrity for tissue culture coating and tailor-made hydrogels in tissue engineering.
  • Huma OsteoGelatin Type A First and only human bone gelatin available in Medium Bloom and High Bloom variants, offering high biodegradability and low toxicity for surface coating and hydrogel encapsulations in regenerative medicine applications.
  • Huma OsteoGelMA Type A Metacrylated human gelatin for tuneable 3D hydrogels that cure under UV light with a photoinitiator such as Irgacure 2959, providing improved mechanical properties and stability of tissue constructs.
  • HumaMatrix Native Human-Derived ECM Human-derived extracellular matrix that mimics the natural cellular environment, available in Solution and Lyophilized forms and ready-to-use as a coating agent or hydrogel component in tissue engineering and regenerative medicine.

Quantifiable outcome

  • 90% of drugs tested on animals ultimately fail in human trials - Ourobionics aims to solve that bottleneck
  • +2 more outcomes

Companies that use Ourobionics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Ourobionics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Ourobionics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • Smart Biomaterials Consortium (SBMC)coreStrategic or Co-development Partner · 14 July 2025Strategic R&D partnership to accelerate development of UNIQUE SKIN - a next-generation in-vitro human skin model using the patented CHIMERA 3D bioprinter. SBMC provides laboratory infrastructure, analytical support, and facilities for testing and scaling up technology.
  • Burn Research LabcoreStrategic or Co-development Partner · 24 March 2025EMARS project collaboration to develop hair-bearing skin constructs for improving treatment of deep wounds and hair loss. Burn Research Lab provides clinical expertise and research facilities.
  • Hair Science CliniccoreStrategic or Co-development Partner · 24 March 2025EMARS project collaboration optimizing hair graft storage conditions, determining conditions for hair regeneration from stem cells, and incorporating stem cells into skin constructs.
  • CyboSensecoreTechnology or IntegrationPartner providing advanced biomarker bioelectronic biosensor technology integrated into the UNIQUE SKIN project for real-time monitoring capabilities.
  • University College London (UCL)flagshipTechnology or IntegrationTechnology invented by Professor Suwan N. Jayasinghe at UCL, licensed to Ourobionics. The bio-electric field technology has been proven in over 150 publications from UCL's BioPhysics Group.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Ourobionics competitors and assessment

Company assessment

Direct peers

  • MIMETAS: Dutch organ-on-chip company selling OrganoPlate products to pharma for drug screening. Directly competes with Ourobionics' UNIQUE-SKIN in preclinical human-tissue testing, with overlapping customer base and GTM motion.
  • Regemat 3D: Spanish bioprinting hardware manufacturer offering modular 3D bioprinters and bioinks. Overlaps with Ourobionics on the CHIMERA device side of the business, serving academic and clinical regenerative medicine customers.
  • Organovo: Pioneer in 3D bioprinted human tissue for preclinical drug testing. Competes head-to-head with Ourobionics in the pharma tissue-model use case and shares the same regulatory tailwind from animal-testing phase-out.
  • BICO (formerly CELLINK): Swedish leader in bioprinting hardware and biomaterials. Sells bioprinters and bioinks to academic and pharma customers globally — directly overlapping with Ourobionics' CHIMERA device and HumaDerm biomaterial offerings. Most comparable peer on business model and customer base.
  • TissUse: German company developing multi-organ-chip (MOC) platforms for substance testing. Comparable product–market fit in pharma/cosmetics preclinical testing and similar European footprint to Ourobionics.
  • Emulate: US organ-on-chip platform using Organs-on-Chips technology for pharma drug development. Competes for the same pharma preclinical-testing budget as Ourobionics' tissue models, particularly in safety and efficacy testing.
  • Aspect Biosystems: Canadian biotech using microfluidic 3D bioprinting to create functional human tissues for therapeutic and drug-discovery applications. Comparable modality (biofabrication platform + tissue products) and target customers.
  • Poietis: French company commercializing laser-assisted bioprinting for tissue engineering and in-vitro models. Overlaps with Ourobionics on bioprinting-hardware-plus-tissue-models positioning, particularly for cosmetic and pharma applications.

Broad incumbents

  • 3D Systems: Large industrial 3D printing incumbent that has explored bioprinting and regenerative medicine applications. Adjacent rather than direct — overlapping on hardware but not focused on Ourobionics' tissue-model niche.
  • Stratasys: Global 3D printing leader with historical investments in bioprinting and medical applications. Comparable on the printing-hardware axis but broader portfolio and not specialized in tissue engineering like Ourobionics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ourobionics social profiles

Digital presence

Ourobionics compliance and trust

Trust signal

Compliance1 record

Ourobionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ourobionics leadership team

Management profile

Number of profiles

Profiles8 records

Ourobionics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ourobionics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ourobionics

What does Ourobionics do?

Ourobionics develops and produces human tissue models with embedded biosensors and the CHIMERA 5-in-1 biofabrication device, leveraging proprietary 3D bio-electric field technology to deposit cells and biomaterials into complex 3D matrices. The company also sells a line of human-derived biomaterials (HumaDerm, Huma OsteoGelatin, HumaMatrix) for tissue engineering and regenerative medicine applications, serving pharmaceutical, cosmetic, chemical, and Medtech customers.

Is Ourobionics a public or private company?

Ourobionics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ourobionics founded?

Ourobionics was founded in 2021. It employs 1 to 10 people.

Where is Ourobionics based?

Ourobionics is headquartered in Utrecht, Netherlands, in the Europe region.

How does Ourobionics make money?

Three revenue lines are on record. CHIMERA Biofabrication Device Sales are the primary driver. The others are human Tissue Models and human-Derived Biomaterials.

Who are Ourobionics's main competitors?

Direct peers on record are MIMETAS, Regemat 3D, Organovo, BICO (formerly CELLINK), TissUse, Emulate, Aspect Biosystems and Poietis. Broad incumbents are 3D Systems and Stratasys.

Does Ourobionics have an API?

No public API is recorded for Ourobionics.

What industry is Ourobionics in?

Ourobionics's product category is Biofabrication Technology. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales